Publications by authors named "J van der Veen"
Menopause affects over a million individuals annually and is characterized by variable and declining ovarian hormones. Decreasing estrogen levels impact energy homeostasis and increases the risk of metabolic disorders. Energy expenditure is largely directed towards thermoregulation, which is modulated in part by estrogen receptor (ER) α expressing neurons in the hypothalamus.
View Article and Find Full Text PDFMulticellular cable bacteria display an exceptional form of biological conduction, channeling electric currents across centimeter distances through a regular network of protein fibers embedded in the cell envelope. The fiber conductivity is among the highest recorded for biomaterials, but the underlying mechanism of electron transport remains elusive. Here, we performed detailed characterization of the conductance from room temperature down to liquid helium temperature to attain insight into the mechanism of long-range conduction.
View Article and Find Full Text PDFArticle Synopsis
- Dupilumab is an effective treatment for moderate-to-severe atopic dermatitis (AD) and severe asthma (SA), but there hasn't been much real-world analysis on its adverse events, particularly those related to the eyes (DAOSD).
- This study analyzed data from patients with AD and SA receiving dupilumab to compare the prevalence of adverse events, focusing on ocular problems and treatment discontinuation rates.
- Results showed a higher prevalence of ocular adverse events in AD patients (62.1%), while SA patients experienced more headaches and injection site reactions, underlining the need for physician awareness when prescribing dupilumab to AD patients and emphasizing the effectiveness of ophthalmic treatments for managing eye-related issues.
Background: Severe asthma (SA) presents a considerable healthcare challenge despite optimal standard treatment. Dupilumab, which is effective in type 2 (T2) SA patients, demonstrates variable responses, categorizing patients as non-responders, partial responders, or those achieving clinical remission. However, real-world response rates remain underexplored.
View Article and Find Full Text PDFDigital biomarkers that remotely monitor symptoms have the potential to revolutionize outcome assessments in future disease-modifying trials in Parkinson's disease (PD), by allowing objective and recurrent measurement of symptoms and signs collected in the participant's own living environment. This biomarker field is developing rapidly for assessing the motor features of PD, but the non-motor domain lags behind. Here, we systematically review and assess digital biomarkers under development for measuring non-motor symptoms of PD.
View Article and Find Full Text PDF